Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1751-553X.2010.01209.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on "Features and Allele Frequency of JAK2 exon 12-mutated Polycythemia Vera in Comparison with JAK2 V617F-mutated Disease".
Arch Med Res
January 2025
Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland. Electronic address:
Features and allele frequency of JAK2 Exon 12-mutated polycythemia vera in comparison with JAK2V617F-mutated disease.
Arch Med Res
October 2024
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taiwan; School of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address:
Background And Aim: JAK2 exon 12 mutation status and the clinical characteristics of patients with polycythemia vera (PV) in Asia remain to be defined.
Method: We analyzed the clinical, molecular, and genetic features and outcomes of patients with PV harboring exon 12 mutation and compared them with the JAK2V617F-mutated patients in Taiwan. JAK2V617F with allele burden was measured by pyrosequencing and/or RT/qPCR.
Differences in the DNA methylome of T cells in adults with asthma of varying severity.
Clin Epigenetics
October 2024
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, 6301 MSRB III, 1150 W Medical Center Dr., Ann Arbor, MI, 48109, USA.
Article Synopsis
- - DNA methylation is crucial in understanding asthma development, yet variations in methylation related to asthma severity in adults are not fully understood.
- - A study involving 35 adults in Beijing analyzed DNA methylation patterns in T cells over time and found significant differences associated with asthma severity and airway inflammation, linked to specific genes and pathways.
- - The research highlights that variations in DNA methylation among adults with differing asthma severities may influence clinical outcomes, indicating potential targets for future asthma treatments or interventions.
ATF3-mediated transactivation of CXCL14 in HSCs during liver fibrosis.
Clin Transl Med
October 2024
Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background And Aims: Myofibroblasts, the primary producers of extracellular matrix, primarily originate from hepatic stellate cells (HSCs), and their activation plays a pivotal role in liver fibrosis. This study aimed to investigate the function of CXC motif ligand 14 (CXCL14) in the progression of liver fibrosis.
Approach And Results: CXCL14 knockdown significantly reduced the extent of liver fibrosis.
Reduced Platelet Activation in Triple-Negative Essential Thrombocythemia Compared with JAK2V617F-Mutated Essential Thrombocythemia.
Clin Cancer Res
December 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Article Synopsis
- Triple-negative essential thrombocytopenia (TN-ET) lacks driver mutations but still meets diagnostic criteria, prompting a study to understand its clinical and molecular characteristics and link them to platelet activation and thrombotic risks.
- A multicenter study compared 138 TN-ET patients to 759 ET patients with the JAK2V617F mutation, revealing that TN-ET patients tended to be younger and had fewer thrombotic events both before diagnosis and during follow-up.
- Results indicated that TN-ET patients had lower platelet activation and reactive oxygen species (ROS) levels, correlating with a reduced risk of thrombosis compared to those with the JAK2V617F mutation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!